| Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study B Pro, R Advani, P Brice, NL Bartlett, JD Rosenblatt, T Illidge, J Matous, ... Journal of clinical oncology 30 (18), 2190-2196, 2012 | 1129 | 2012 |
| Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project M Federico, M Bellei, L Marcheselli, S Luminari, A Lopez-Guillermo, ... Journal of Clinical Oncology 27 (27), 4555-4562, 2009 | 874 | 2009 |
| The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ... Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022 | 742 | 2022 |
| Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy B Coiffier, B Pro, HM Prince, F Foss, L Sokol, M Greenwood, D Caballero, ... Journal of Clinical Oncology 30 (6), 631-636, 2012 | 741 | 2012 |
| Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study OA O'Connor, B Pro, L Pinter-Brown, N Bartlett, L Popplewell, B Coiffier, ... Journal of Clinical Oncology 29 (9), 1182-1189, 2011 | 698 | 2011 |
| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ... The Lancet 393 (10168), 229-240, 2019 | 692 | 2019 |
| High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose … JE Romaguera, L Fayad, MA Rodriguez, KR Broglio, FB Hagemeister, ... Journal of Clinical Oncology 23 (28), 7013-7023, 2005 | 689 | 2005 |
| Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma A Goy, A Younes, P McLaughlin, B Pro, JE Romaguera, F Hagemeister, ... Journal of Clinical Oncology 23 (4), 667-675, 2005 | 660 | 2005 |
| Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients BS Dabaja, D Suki, B Pro, M Bonnen, J Ajani Cancer: Interdisciplinary International Journal of the American Cancer …, 2004 | 650 | 2004 |
| Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial HM Prince, YH Kim, SM Horwitz, R Dummer, J Scarisbrick, P Quaglino, ... The Lancet 390 (10094), 555-566, 2017 | 564 | 2017 |
| Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial YH Kim, M Bagot, L Pinter-Brown, AH Rook, P Porcu, SM Horwitz, ... The lancet oncology 19 (9), 1192-1204, 2018 | 540 | 2018 |
| Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins CM Bollard, S Gottschalk, V Torrano, O Diouf, S Ku, Y Hazrat, G Carrum, ... Journal of Clinical Oncology 32 (8), 798-808, 2014 | 528 | 2014 |
| Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma JE Romaguera, LJ Medeiros, FB Hagemeister, LE Fayad, MA Rodriguez, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 322 | 2003 |
| Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell … JE Romaguera, LE Fayad, L Feng, K Hartig, P Weaver, MA Rodriguez, ... British journal of haematology 150 (2), 200-208, 2010 | 308 | 2010 |
| Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies S Faderl, DA Thomas, S O'Brien, G Garcia-Manero, HM Kantarjian, ... Blood, The Journal of the American Society of Hematology 101 (9), 3413-3415, 2003 | 308 | 2003 |
| Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma IF Khouri, MS Lee, RM Saliba, G Jun, L Fayad, A Younes, B Pro, ... Journal of Clinical Oncology 21 (23), 4407-4412, 2003 | 260 | 2003 |
| Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma CS Tam, R Bassett, C Ledesma, M Korbling, A Alousi, C Hosing, ... Blood, The Journal of the American Society of Hematology 113 (18), 4144-4152, 2009 | 257 | 2009 |
| Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas MD Anderson Cancer Center Q Liu, L Fayad, F Cabanillas, FB Hagemeister, GD Ayers, M Hess, ... Journal of Clinical Oncology 24 (10), 1582-1589, 2006 | 255 | 2006 |
| Temsirolimus has activity in non–mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago Phase II Consortium SM Smith, K Van Besien, T Karrison, J Dancey, P McLaughlin, A Younes, ... Journal of Clinical Oncology 28 (31), 4740-4746, 2010 | 248 | 2010 |
| Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma B Pro, R Advani, P Brice, NL Bartlett, JD Rosenblatt, T Illidge, J Matous, ... Blood, The Journal of the American Society of Hematology 130 (25), 2709-2717, 2017 | 246 | 2017 |
